Kentucky fried trials: Novartis' finger-prickin' recipe for efficiency
This article was originally published in Scrip
"In the future, a patient in a clinical trial may get a box that contains all of the instructions and perhaps a smart device linking them to data collection."
You may also be interested in...
Charting the executive gender mix across 384 companies from mid-2014 to mid-2019 demonstrates that C-suite gender balance in pharma is moving towards a point that more closely reflects its total workforce, but that progress has been slow and that there is a long road to travel before the transformation is complete.
With gender diversity only slowly increasing in biopharma c-suites, Scrip spoke to executives from five companies about the importance of change.
In a flat month, the market value of big pharma changed little overall. But the balance of power in immuno-oncology did shift significantly.